U-01 is under clinical development by Shanghai Unicar-Therapy Bio-Medicine Technology and currently in Phase I for B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia). According to GlobalData, Phase I drugs for B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia) have a 90% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how U-01’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
U-01 overview
U-01 is under development for the treatment of B cell acute lymphocytic leukemia, relapsed or refractory acute lymphoblastic leukemia, and relapsed/refractory acute myeloid leukemia. The drug candidate consists of chimeric antigen receptor (CAR) modified T-cells which act by targeting CD19 expressing cancer cells. It is developed based on SMART(siRNA mediated acquired reprogramming technology) platform. It was under development for Hodgkin Lymphoma, non Hodgkin lymphoma and chronic lymphocytic leukemia.
Shanghai Unicar-Therapy Bio-Medicine Technology overview
Shanghai Unicar-Therapy Bio-Medicine Technology., is a pharmaceutical company and a tumor immunotherapy technology developer. The company is headquartered China.
For a complete picture of U-01’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
